
    
      Eligible patients will be stratified by HIV-1 RNA level into 2 populations: 1) >=
      5,000-30,000 HIV-1 RNA, 2) > 30,000 HIV-1 RNA. All patients will be randomized to 1 of 3
      treatment arms: Arm A - Saquinavir soft gel capsules (SQV SGC) + 2 new nucleoside analogs
      (reverse transcriptase inhibitors [RTIs]), Arm B - SQV SGC + nelfinavir + stavudine (d4T) or
      a new RTI, or Arm C - SQV SGC + ritonavir + d4T or a new RTI. All patients will undergo
      plasma HIV-1 RNA determinations, CD4 lymphocyte counts, hematology and chemistry blood work
      at baseline, weeks 4, 8, 12, 16 and 24.
    
  